CRLX101: Additional Phase Ib/IIa data

Data from 18 patients with third- through sixth-line metastatic RCC in a dose-escalation, U.S. Phase Ib/IIa trial showed that CRLX101 plus Avastin bevacizumab led to an ORR of 22%, including 4 partia...